Physician profile
Gerald L Ray
NPI 1720067119
$4,236.30
in general payments reported to CMS, 2019-2025
37 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $816 · 2020: $421 · 2021: $655 · 2022: $1,386 · 2023: $508 · 2024: $15.38 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $543.23 | 2019-2025 | |
| Lilly USA, LLC | $514.55 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $481.02 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $438.17 | 2019-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $359.41 | 2019-2023 | Shingrix, Trelegy Ellipta |
| Pfizer INC. | $249.41 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $247.29 | 2022 | |
| Exact Sciences Corporation | $172.39 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Antares Pharma, INC. | $130.01 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.87 | 2019-2022 | |
| Echosens North America, INC. | $86.65 | 2025 | Fibroscan |
| Astellas Pharma US INC | $70.83 | 2021-2025 | Veozah |
| Merck Sharp & Dohme LLC | $68.53 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $62.53 | 2019-2022 | |
| Abbott Laboratories | $54.64 | 2021-2025 | Eterna |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $50.81 | 2019-2020 | |
| Ibsa Pharma INC. | $49.45 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $46.66 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.58 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $45.39 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $40.86 | 2022-2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.38 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.46 | 2020-2023 | Trintellix |
| Amarin Pharma, INC. | $35.03 | 2019-2022 | |
| Amgen INC. | $34.29 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $27.58 | 2020-2021 | |
| Avion Pharmaceuticals | $26.46 | 2022 | |
| Supernus Pharmaceuticals, INC. | $22.99 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.20 | 2023 | Rexulti |
| Vertical Pharmaceuticals, LLC | $16.56 | 2019 | |
| Dexcom, INC. | $16.14 | 2022 | |
| Phadia US INC. | $15.33 | 2025 | Immunocap |
| Ultragenyx Pharmaceutical INC. | $15.09 | 2021 | |
| Clarus Therapeutics INC. | $14.23 | 2021 | |
| Sanofi Pasteur INC. | $13.56 | 2019 | |
| Upsher-Smith Laboratories LLC | $12.96 | 2019 | |
| Therapeuticsmd, INC. | $11.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.